% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Peterziel:186513,
author = {H. Peterziel$^*$ and N. Jamaladdin$^*$ and D. ElHarouni$^*$
and X. Gerloff$^*$ and S. Herter$^*$ and P. Fiesel$^*$ and
Y. Berker$^*$ and M. Blattner-Johnson$^*$ and K. Schramm$^*$
and B. Jones$^*$ and D. Reuss and L. Turunen and A.
Friedenauer$^*$ and T. Holland-Letz$^*$ and M. Sill$^*$ and
L. Weiser$^*$ and C. Previti$^*$ and G. Balasubramanian$^*$
and N. U. Gerber and J. Gojo and C. Hutter and I. Øra and
O. Lohi and A. Kattamis and B. de Wilde and F.
Westermann$^*$ and S. Tippelt and N. Graf and M. Nathrath
and M. Sparber-Sauer and A. Sehested and C. M. Kramm and U.
Dirksen and O. Kallioniemi and S. Pfister$^*$ and C. M. van
Tilburg$^*$ and D. Jones$^*$ and J. Saarela and V.
Pietiäinen and N. Jäger$^*$ and M. Schlesner$^*$ and A.
Kopp-Schneider$^*$ and S. Oppermann$^*$ and T. Milde$^*$ and
O. Witt$^*$ and I. Oehme$^*$},
title = {{D}rug sensitivity profiling of 3{D} tumor tissue cultures
in the pediatric precision oncology program {INFORM}.},
journal = {npj precision oncology},
volume = {6},
number = {1},
issn = {2397-768X},
address = {[London]},
publisher = {Springer Nature},
reportid = {DKFZ-2022-03215},
pages = {94},
year = {2022},
note = {#EA:B310#LA:B310#},
abstract = {The international precision oncology program INFORM enrolls
relapsed/refractory pediatric cancer patients for
comprehensive molecular analysis. We report a two-year pilot
study implementing ex vivo drug sensitivity profiling (DSP)
using a library of 75-78 clinically relevant drugs. We
included 132 viable tumor samples from 35 pediatric oncology
centers in seven countries. DSP was conducted on
multicellular fresh tumor tissue spheroid cultures in
384-well plates with an overall mean processing time of
three weeks. In 89 cases $(67\%),$ sufficient viable tissue
was received; 69 $(78\%)$ passed internal quality controls.
The DSP results matched the identified molecular targets,
including BRAF, ALK, MET, and TP53 status. Drug
vulnerabilities were identified in $80\%$ of cases lacking
actionable (very) high-evidence molecular events, adding
value to the molecular data. Striking parallels between
clinical courses and the DSP results were observed in
selected patients. Overall, DSP in clinical real-time is
feasible in international multicenter precision oncology
programs.},
cin = {B310 / HD01 / B240 / B062 / B300 / B360 / C060 / W610 /
B087},
ddc = {610},
cid = {I:(DE-He78)B310-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B240-20160331 / I:(DE-He78)B062-20160331 /
I:(DE-He78)B300-20160331 / I:(DE-He78)B360-20160331 /
I:(DE-He78)C060-20160331 / I:(DE-He78)W610-20160331 /
I:(DE-He78)B087-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:36575299},
doi = {10.1038/s41698-022-00335-y},
url = {https://inrepo02.dkfz.de/record/186513},
}